File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Drug treatment for obesity in the post-sibutramine era

TitleDrug treatment for obesity in the post-sibutramine era
Authors
Issue Date2011
PublisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/
Citation
Drug Safety, 2011, v. 34 n. 8, p. 641-650 How to Cite?
AbstractObesity is a major health problem worldwide. It is associated with cardiovascular diseases, diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are essential; pharmacological therapy may be added for obese patients or overweight patients with cardiovascular risk factors. Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis. It reduces bodyweight by about 4.2kg after 12 months, and improves blood glucose and lipids; however, it can increase heart rate and blood pressure. In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients. There is now a clear need to find anti-obesity drugs that are effective and safe in the long term. © 2011 Adis Data Information BV. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/137409
ISSN
2015 Impact Factor: 3.206
2015 SCImago Journal Rankings: 1.359
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2011-08-26T14:24:31Z-
dc.date.available2011-08-26T14:24:31Z-
dc.date.issued2011en_HK
dc.identifier.citationDrug Safety, 2011, v. 34 n. 8, p. 641-650en_HK
dc.identifier.issn0114-5916en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137409-
dc.description.abstractObesity is a major health problem worldwide. It is associated with cardiovascular diseases, diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are essential; pharmacological therapy may be added for obese patients or overweight patients with cardiovascular risk factors. Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis. It reduces bodyweight by about 4.2kg after 12 months, and improves blood glucose and lipids; however, it can increase heart rate and blood pressure. In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients. There is now a clear need to find anti-obesity drugs that are effective and safe in the long term. © 2011 Adis Data Information BV. All rights reserved.en_HK
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/en_HK
dc.relation.ispartofDrug Safetyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAnti-Obesity Agents - therapeutic useen_HK
dc.subject.meshAppetite Depressants - adverse effectsen_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshCardiovascular Diseases - chemically induceden_HK
dc.subject.meshChilden_HK
dc.subject.meshCyclobutanes - adverse effectsen_HK
dc.subject.meshHeart Rate - drug effectsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshObesity - complications - drug therapyen_HK
dc.subject.meshRisken_HK
dc.subject.meshTime Factorsen_HK
dc.titleDrug treatment for obesity in the post-sibutramine eraen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2165/11592040-000000000-00000en_HK
dc.identifier.pmid21751825-
dc.identifier.scopuseid_2-s2.0-79960378021en_HK
dc.identifier.hkuros190892en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79960378021&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue8en_HK
dc.identifier.spage641en_HK
dc.identifier.epage650en_HK
dc.identifier.isiWOS:000293720400004-
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats